Erythropoietic response and outcomes in kidney disease and type 2 diabetes

New England Journal of Medicine

Volumn 363, Issue 12, 2010, Pages 1146-1155

  Solomon, Scott D ^a   Uno, Hajime ^a   Lewis, Eldrin F ^a   Eckardt, Kai Uwe ^d   Lin, Julie ^b   Burdmann, Emmanuel A ^e   De Zeeuw, Dick ^f   Ivanovich, Peter ^g   Levey, Andrew S ^c   Parfrey, Patrick ^h   Remuzzi, Giuseppe ⁱ   Singh, Ajay K ^b   Toto, Robert ^j   Huang, Fannie ^k   Rossert, Jerome ^k   McMurray, John J V ^l   Pfeffer, Marc A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g NORTHWESTERN UNIVERSITY   (United States)

^h Health Sciences Centre St John's   (Canada)

ⁱ MARIO NEGRI INST PHARMACOL RES   (Italy)

^j UNIVERSITY OF TEXAS AT DALLAS   (United States)

^k AMGEN INC   (United States)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ERYTHROPOIETIN; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; ANTIANEMIC AGENT;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANEMIA; BLOOD; CARDIOVASCULAR DISEASES; CHI SQUARE DISTRIBUTION; CHRONIC KIDNEY FAILURE; COMPLICATION; FEMALE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANEMIA; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; STROKE;

EID: 77956704796     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1005109     Document Type: Article

References (24)

1. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
2. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98. (Pubitemid 44749317)
3. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84. (Pubitemid 44749316)
4. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8. (Pubitemid 46188479)
5. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90. (Pubitemid 28385655)
6. Szczech LA, Barnhart HX, Sapp S, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010;77:239-46.
7. KDOQI Clinical Practice Guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
8. The Renal Association. Complications of CKD. (Accessed August 24, 2010, at http://www.renal.org/Clinical/Guidelines Section/ComplicationsofCKD. aspx#Summary-S3.)
9. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:121-32. (Pubitemid 38072623)
10. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005;16:3403-10. (Pubitemid 46179344)
11. Messana JM, Chuang CC, Turenne M, et al. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comborbidity- adjusted model. Am J Kidney Dis 2009;53:503-12.
12. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007;22:794-800. (Pubitemid 46351687)
13. López-Gómez JM, Portolés JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 2008;111:S75-S81.
14. Kausz AT, Solid C, Pereira BJ, Collins AJ, St Peter W. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? Am J Kidney Dis 2005;45:136-47.
15. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-8.
16. Bradbury BD, Danese MD, Gleeson M, Critchlow CW. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin J Am Soc Nephrol 2009;4:630-7.
17. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
18. Mix TC, Brenner RM, Cooper ME, et al. Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005;149:408-13.
19. Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1077-83.
20. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007;18:382-93.
21. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007;12:321-30.
22. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52:727-36.
23. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents - time for a reevaluation. N Engl J Med 2010;362:189-92.
24. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010;303:857-64.